Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Locally Advanced Breast Cancer
Interventions: DRUG: Gemcitabine|DRUG: Bevacizumab
Sponsor: Eli Lilly and Company
Collaborators: Genentech, Inc.